Navigation Links
VA-NIH Study Offers Hope for Parkinson's Patients
Date:1/13/2009

so developing side effects from the drugs, such as involuntary face, arm or leg movements.

Researchers followed the patients for six months, finding:

  • Patients who received DBS gained an average of 4.6 hours per day of good motor control and few or no involuntary movements, compared with no gain for those on medical therapy alone;
  • 71 percent of DBS patients showed significant gains in motor function, compared with only 32 percent of drug therapy patients; and
  • Serious adverse side effects were nearly four times more common in the DBS group, but almost all of these effects in both groups were resolved during the six-month study. The most common side effects from DBS were infections, falls, depression, gait and balance problems, and pain.

Lead authors and study co-chairs were Frances Weaver, PhD, a researcher with the Center for Management of Complex Chronic Care at the Hines VA Hospital near Chicago, and Dr. Kenneth Follett, a neurosurgeon at the Omaha VA Medical Center and University of Nebraska. They emphasize that besides the higher likelihood of serious side effects with DBS compared with drug therapy, another drawback of the procedure is that, although it generally improves movement, it does little to help other Parkinson's symptoms such as depression, decline in mental ability, gait and balance problems, and trouble with gastrointestinal, urinary or sexual function.

"The results of the study should not be over- or under-stated," said Dr. Michael Kussman, VA's Under Secretary for Health. "Still, there are many good candidates for DBS among patients with Parkinson's disease whom we treat in VA."

The trial was sponsored by VA's Cooperative Studies Program and the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health. Additional support came from Medtronic, wh
'/>"/>

SOURCE U.S. Department of Veterans Affairs
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...Newswire-FirstCall/ -- Recession in domestic and i...r Allied Healthcare Products in the first quarter ..., Sales declines pushed Allied into a loss for th... $745,000, or negative 9 cents per share, compared...0, or 3 cents per share. ,, Sales fell about 2...
(Date:11/6/2009)...Newswire/ -- Trius Therapeutics, Inc. announced to...Form S-1 with the U.S. Securities and Exchange Com...c offering of shares of its common stock. All shar...will be offered by the Company. ,, Credit Suiss...ing manager, Piper Jaffray & Co. is acting as ...
(Date:11/6/2009)...6 Repossessions and liquidations o...d quarter of 2009 declined as compared to similar ...ement,s NasTrac Quarterly Index (NQI). The figure...both repossessions and orderly liquidations, also ...ction and printing equipment, offering mixed news ...
Breaking Medicine Technology:Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 3NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 4Families Need to Know When Dementia Becomes Terminal 59478 1Families Need to Know When Dementia Becomes Terminal 59478 2Families Need to Know When Dementia Becomes Terminal 59478 3CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 59475 1CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 59475 2CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 59475 3CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 59475 4Fine Tuning Prosthetic Hands to Restore a Sense of Touch 59472 1Fine Tuning Prosthetic Hands to Restore a Sense of Touch 59472 2
...rstCall/ -- Avalon,Pharmaceuticals, Inc. , today a...Phase I clinical trial of AVN944 in hematologic,ma...ose of the U.S.,financial markets. The Company wil...0, 2007 at 8 a.m. Eastern Time. Interested,investo... public,can listen to the call over the Internet f...
... 2007 - Can-Fite,BioPharma (TASE:CFBI), a biotechn...e Exchange, proceeds with the development of its,t...ch is currently,in clinical trials and CF102, whic...will present at the EUALR annual congress of,rheum... effective,anti-inflammatory activity for CF502. T...
Other Medicine Technology:Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial 2Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial 3Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2
(Date:11/7/2009)...USTON, Nov. 7 Members o...duce an emergency resolution rescinding the AMA,s ...icians that they are responsible to their PATIENTS...kes, Director of Policy for the Association of Ame...ine, a coalition of other medical groups. ,, "...
(Date:11/7/2009)...Brown: "Faithful Catholics have a responsibility t...gotiate the status quo." ,, WASHINGTON, Nov. ...ue president Judie Brown released the following st...ll support Speaker Nancy Pelosi,s Affordable Healt...endment preserving the status quo for abortion is ...
(Date:11/7/2009)...SHINGTON, Nov. 7 Speake... availability this afternoon following a Democrati...Caucus Room. Below are the Speaker,s opening rema...it was a great occasion for us to receive the Pres...l be making history with our vote and making progr...
(Date:11/7/2009)...O, Nov. 7 The Public Relations Society of America...low on Diane Gage Lofgren, senior vice president o... Permanente, tonight at a ceremony at PRSA,s 2009 ... inducted into the PRSA College of Fellows is one ...id Michael Herman, APR, SAGE, Fellow PRSA, and 200...
(Date:11/7/2009)...ight back to stem a growing problem across the U.S... Nearly half of students at four-year colleges do ...inge drinking -- downing five or more alcoholic dr...tifying alcohol as a drug," said Jenny Hwang, asso...ing center at Stony Brook University on Long Islan...
Breaking Medicine News(10 mins):Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 3Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 3
...s a condition of the skin that affects more than 8...lts. While stress has often been cited // as a sou...d until now. Twenty-two university students par...ss for students. Stress levels were recorded using...
...search shows that pregnant women are at a higher r... legs syndrome is marked by // an urge to move the...umbness, tingling or burning sensations. Patients ...ptoms tend to progress with age. Researchers sa...
... and neglected children are much more likely to de...en who were not abused or neglected //, according ... self-destructive behaviors such as smoking, drug ...tional, physical or sexual abuse, physical neglect...
...er to help combat an increased risk for life-threa... and type II diabetes would be well // advised to ...ndard twice a day, according to a new study. Re...vascular disease. Results showed that blood sugar ...
...nt British study says that Man's best friend might...eptionally sensitive noses, // dogs can smell odor...dogs of varying breeds and ages were trained over ...rom six control group participants and one bladder...
...ing to a recent study researchers say the antidepr...nificantly reduce symptoms of fibromyalgia in wom...serotonin and // norepinephrine, two of the brain’...ss, headaches, sleep disturbances, and fatigue. Th...
Other Medicine News:
Ezy Wrap® Economy Knee Immobilizer
QualCraft™ Knee w/MultiLock Polyamide Hinge
...tic benefits of controlled compression to minimize...ain. The cuff is anatomically designed to complete... Knee Cryo/Cuff is available in three sizes for ad...signed for children 1 - 7 years of age. A sterile ...
DuraSoft Shoulder Wrap and Back Wrap
Medicine Products: